PROCEPT BioRobotics (PRCT) AI Stock Analysis

• Market Cap: $2.13B
• Dividend Yield: N/A
• Average Volume (3M): 1.37M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.25
• Revenue Growth: 55.71%
• EPS Growth: 24.37%
• Country: US
• Employees: 756
• Sector: Healthcare
• Sector Strength: 52
• Industry: Medical - Devices
• EPS (TTM): -0.35
• Shares Outstanding: 55,635,940
• 10 Day Avg. Volume: 906,268
• 30 Day Avg. Volume: 1,374,015
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.39
• Enterprise Value/Revenue: 11.92
• Enterprise Value/Gross Profit: 19.17
• Enterprise Value/Ebitda: -36.83
• 1Y Price Target: $69.00
• Price Target Upside: 69.62% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11

• Rating: 53 Neutral
• Price Target: $41.00 ▲(0.79% Upside)

The overall stock score reflects strong revenue growth and positive earnings call sentiment, tempered by ongoing financial challenges and bearish technical indicators. The new CEO appointment is a positive step but does not significantly alter the current financial and market conditions.

Positive Factors

Financial Performance

Procept Biorobotics Corp pre-announced second quarter revenue 4% above consensus, demonstrating strong commercial momentum.

Growth Potential

All indications are positive for near- and long-term growth in a market only 15% penetrated with TAM expansion execution ongoing.

Leadership

Larry Wood, an industry veteran, is appointed as the new CEO of Procept Biorobotics Corp, bringing valuable perspective and expertise.

Negative Factors

Guidance

The updated guidance came in potentially softer than expected, with raised FY25 sales guidance implying reduced sales compared to consensus.

Investor Concerns

The newly announced CCO transition on top of a CEO transition will create concerns about the business.

Stock Performance

Procept Biorobotics Corp shares are down 27% year-to-date, despite the company's strong financial performance.

PROCEPT BioRobotics Business Overview & Revenue Model

Company Description

PROCEPT BioRobotics Corporation (PRCT) is a medical technology company specializing in the development of innovative robotic solutions for the treatment of urological diseases. The company's flagship product, the AquaBeam Robotic System, utilizes advanced imaging and robotics to perform minimally invasive surgery for benign prostatic hyperplasia (BPH), a common condition affecting older men. By focusing on enhancing patient outcomes and reducing the side effects associated with traditional surgical methods, PROCEPT BioRobotics aims to revolutionize the standard of care in the urology sector.

How the Company Makes Money

PROCEPT BioRobotics generates revenue primarily through the sale and leasing of its AquaBeam Robotic System to healthcare providers and hospitals. The company also earns income from the sale of disposable handpieces and accessories used in conjunction with the system during procedures. In addition, service and maintenance contracts provide a recurring revenue stream, as customers require ongoing support and system upkeep. Partnerships with healthcare organizations and collaborations with medical professionals further bolster the company's market presence and contribute to its financial growth by driving adoption and expanding its customer base.

PROCEPT BioRobotics Financial Statement Overview

Summary

PROCEPT BioRobotics shows strong revenue growth and a robust equity position, indicative of potential long-term stability. However, persistent operating losses and negative cash flows highlight ongoing challenges in profitability and cash management. Continued focus on reducing operational costs and improving cash flow is essential for future sustainability.

Income Statement

The company exhibits strong revenue growth with a TTM increase of 10.96% from the previous year. However, it is still operating at a loss with a negative net profit margin of -36.20% and negative EBIT and EBITDA margins, indicating challenges in achieving profitability. The gross profit margin of 62.19% suggests good product pricing but is offset by high operating expenses.

Balance Sheet

The balance sheet shows a healthy equity position with a substantial equity ratio of 74.93%, indicating low leverage and strong capital structure. The debt-to-equity ratio is 0.20, reflecting modest debt levels compared to equity, which enhances financial stability. However, the company has not yet achieved positive returns on equity due to ongoing net losses.

Cash Flow

The company has a negative free cash flow, although there is a slight improvement with a growth rate of 14.74% in TTM. Operating cash flow remains negative and the operating cash flow to net income ratio is unfavorable, indicating ongoing cash flow challenges. Despite these issues, the company secured significant financing, enhancing liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	249.12M	224.50M	136.19M	75.01M	34.47M	7.72M
Gross Profit	154.96M	137.10M	71.05M	37.09M	15.87M	-1.25M
EBITDA	-80.65M	-82.00M	-98.09M	-77.65M	-51.06M	-45.05M
Net Income	-90.19M	-91.41M	-105.90M	-93.58M	-62.38M	-58.26M
Balance Sheet
Total Assets	519.38M	534.02M	404.72M	309.33M	337.02M	125.97M
Cash, Cash Equivalents and Short-Term Investments	316.21M	333.73M	257.22M	221.86M	304.32M	100.13M
Total Debt	81.81M	80.25M	79.20M	77.32M	54.10M	54.76M
Total Liabilities	130.22M	131.80M	123.97M	112.26M	69.93M	308.87M
Stockholders Equity	389.16M	402.22M	280.75M	197.07M	267.09M	-182.89M
Cash Flow
Free Cash Flow	-88.21M	-103.62M	-133.21M	-83.03M	-57.93M	-48.58M
Operating Cash Flow	-83.91M	-99.21M	-108.00M	-80.38M	-57.33M	-48.34M
Investing Cash Flow	-4.30M	-4.41M	-25.21M	-2.65M	-592.00K	-233.00K
Financing Cash Flow	178.84M	180.13M	167.79M	3.61M	262.12M	106.77M

PROCEPT BioRobotics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 40.68
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRCT, the sentiment is Negative. The current price of 40.68 is above the 20-day moving average (MA) of 39.79, below the 50-day MA of 49.05, and below the 200-day MA of 63.37, indicating a neutral trend. The MACD of -2.61 indicates Negative momentum. The RSI at 42.80 is Neutral, neither overbought nor oversold. The STOCH value of 30.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRCT.

PROCEPT BioRobotics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UFPT	73 Outperform	$1.60B	24.03	19.29%	―	40.98%	34.80%
AXGN	69 Neutral	$735.28M	―	-4.48%	―	17.17%	72.68%
ITGR	65 Neutral	$3.75B	47.23	5.15%	―	7.21%	-23.29%
LIVN	61 Neutral	$3.18B	30.62	-17.87%	―	8.57%	-1154.64%
XTNT	55 Neutral	$82.10M	―	-9.80%	―	15.16%	-39.18%
PRCT	53 Neutral	$2.13B	―	-26.40%	―	55.71%	24.37%
Sector *	51 Neutral	$7.95B	-0.40	-41.62%	2.21%	22.29%	-1.85%

PROCEPT BioRobotics Corporate Events

PROCEPT BioRobotics Appoints New CEO Larry L. Wood

On July 23, 2025, PROCEPT BioRobotics announced the appointment of Larry L. Wood as President and CEO, effective September 2, 2025, succeeding Dr. Reza Zadno, who will retire on September 1, 2025. Dr. Zadno will transition to a consulting role, having led the company through significant growth, including the adoption of Aquablation therapy and a successful public offering. Mr. Wood, with over 40 years of experience in the medical technology industry, joins from Edwards Lifesciences and has been a member of PROCEPT BioRobotics’ board since 2024. The company also pre-announced second-quarter 2025 revenue of approximately $79.2 million, representing an annual growth of 48%.

PROCEPT BioRobotics Elects Board at Annual Meeting

On June 10, 2025, PROCEPT BioRobotics held its annual stockholders meeting where all director nominees were elected to the board until 2028. Additionally, the selection of PricewaterhouseCoopers LLP as the independent accounting firm for 2025 was ratified, and the executive compensation package was approved.